Kraepelin had used earlier. The condition was renamed delusional disorder because of concerns that the common clinical term paranoid was vague in meaning and often applied inappropriately (3) . This condition is no longer regarded as rare, but systematic study of delusional disorder and the development of effective treatment remain unfinished tasks.
Indeed, in the history of medicine, discovery of successful treatment often precedes basic understanding of a disorder. Riding and Munro reported on the use of the antipsychotic agent pimozide to treat several cases of what was termed "monosymptomatic hypochondriacal psychosis" (4) . They replicated their work for additional publications (5, 6) , indicating that a form of delusional disorder (the somatic subtype) was treatable with this medication. They further found that, in unimproved cases, nonadherence to medication regimens was an important and frequent factor affecting outcome. Despite such reports, the impression of most practitioners has been that antipsychotic medications are of marginal value and that this condition is treatment-resistant (7).
Munro and Mok reviewed clinicians' published experience with antipsychotic treatment of delusional disorder from the 1960s to 1994 (5) . They critically analyzed approximately 1000 articles on delusional disorder dating from 1961, with most published between 1980 and 1994. Noting that case descriptions were often incomplete, they only selected cases where the patients' presentation conformed to DSM-IV criteria (1) . Of the 257 cases finally accumulated, only 209 cases were sufficiently detailed to report meaningfully on treatment. The authors concluded that even this refined body of data was disparate and confusing and that only the "broadest conclusions" could be drawn. Nevertheless, they asserted that delusional disorder was an illness with a reasonably good prognosis when adequately treated. They also observed that treatment response was positive regardless of the specific delusional content (the subtype) of the disorder. Interestingly, they proposed that pimozide appeared to show the strongest evidence of good results in clinical reports.
This report extends those observations and reviews the current status of the treatment of delusional disorder, paying special attention to recent experience with second-generation antipsychotic agents.
Methods
Our initial intent was to capture all reports of delusional disorder published since 1994. We searched for cases of the disorder through Medline queries of journal articles, including letters to editors, and also examined the Cochrane database and book chapters. In addition, we contacted pharmaceutical companies producing major antipsychotic drugs for case reports of delusional disorder treatment. This search strategy yielded 153 articles on delusional disorder, which we then assessed for clarity and completeness, treatment, and outcome descriptions. Articles were published between 1994 and 2004. Of the 153 articles, 68 had adequate diagnostic rigour (criteria and method of diagnosis were identified). Fewer still (n = 35) contained sufficient information to characterize treatment. Of 34 articles reporting clear outcome data, only 9 assessed treatment outcome systematically with objective measures, while the remaining 25 relied on clinician judgment for outcome estimates.
After excluding cases of organic delusional disorder, our selection process identified 224 cases of delusional disorder. However, sufficient treatment information was available for only 136 cases, with the reports providing outcome data and follow-up information for 134. As Munro and Mok commented in their previous review (5), the treatment regimens described were seldom explicit concerning, for example, the order of medication application when multiple medications had been tried.
Results

Demographics
Consistent with Munro and Mok's 1995 review (5), women outnumbered men in a ratio of nearly 4 to 3 (57% compared with 43%) in the newer set of cases (Table 1a) . However, this sample of recent cases also showed some differences. Although patients with delusional disorder were similar in mean age (48.8 years for men; 44.9 years for women) to their counterparts of a decade ago (44.3 years for men; 51.2 years for women), women were no longer significantly older than men at the time of case identification. Age ranged from 29 to 78 years among women and from 17 to 72 years among men; these ranges are similar to prior observations. However, most patients in our sample were in their late 30s.
The average follow-up period (10 months; range, 1 to 36 months) for this newer group was shorter than for the earlier sample (22 months; range, 0 to 36 months).
Most subjects had delusions with a persecutory theme (n = 85) (Table 1b) . Somatic delusions was the delusion subtype with the greatest recorded detail about course, treatment, and follow-up (n = 80). Twelve patients experienced a mixture of delusions.
Comorbid Conditions
Recent cases of delusional disorder differed from those reviewed in 1995 in the occurrence of medical and psychiatric comorbid disorders (Table 2 ). Among Munro and Mok's cases, the most prevalent comorbid conditions were also known risk factors for delusional disorder (5) . For example, head injury or trauma and history of substance abuse were common. In our sample, depression or depressive symptoms were most commonly mentioned as comorbid conditions (n = 51, 23%). Only 5 patients (2.2%) were identified as having organic brain disorder or head trauma, and 2 patients (1%) had a known history of substance abuse. It seems highly likely that more patients in our current sample would have such comorbid disorders, but they may not have been recorded. Strikingly, there was no mention in the newer articles of family history of mental illness.
Outcome
We classified outcomes in 3 categories-recovered, improved, and no improvement-which were determined by symptomatology at follow-up. Thus a patient who was symptom-free at the time of follow-up was identified as recovered, whereas one whose symptoms had not changed was considered as showing no improvement. A caveat here is that the description of recovery in many cases relied on clinical judgment rather than on objective measures. However, where actual numbers were presented, recovery was defined as a clinically significant reduction in scores on the assessment tool used. Outcomes are summarized in Tables 3a,  3b , and 3c.
Adherence
Only one article discussed adherence issues (9); the authors noted that 12 (5.4%) of their patients might not have taken their medications exactly as prescribed. This finding likely underestimates actual nonadherence. In several articles, sporadic comments suggested that nonadherence was a problem in an infrequent number of cases. Again, these observations probably underestimate actual nonadherence.
Use of Medications
The introduction of second-generation (atypical) antipsychotic medications may have appreciably changed the treatment of delusional disorder. Munro and Mok focused much attention on the efficacy differences found between pimozide and other neuroleptic medications (the typical antipsychotics), but trends in medication therapy have changed. First, polypharmacy regimens have emerged in the treatment of delusional disorder. Many of these patients also report depressive symptoms, and most patients now are treated with both an antipsychotic and an antidepressant medication. Second, patients commonly receive more than one antipsychotic medication over the course of their illness. This is important to note because, although the symptoms may ultimately resolve, the exact source of success is not always clear. Third, treatment regimens often mention cognitivebehavioural therapy or even electroconvulsive therapy with concomitant antipsychotic medication. Most reports emphasize medication treatment, primarily with antipsychotic agents. Treatment actually encompasses various approaches, including medication, although evidence of such mixed strategies is meagre.
In the current sample, nearly 45% of the patients with delusional disorders received pimozide. Using the Wilcoxon rank sum test, we found a difference in recovery rates that approached statistical significance (P = 0.055) between those who were treated with pimozide and those who were not, independent of delusion type, yet the raw data suggested that the trend from the earlier review was reversed. Among the group treated with pimozide, 77.9% were either fully recovered or improved at follow-up (Table 3c) . Among patients receiving all other antipsychotic agents (including clozapine), 93.9% showed full recovery or improvement. In this newer sample, no particular method of medication treatment produced a more favourable outcome. Most patients, regardless of which medication they used, had a favourable outcome after treatment. 
Comparison of Conventional With Second-Generation Antipsychotic Treatment
When we examined the available outcome data for our patient sample, we found no significant differences in outcome by type of medication used. Using the Wilcoxon rank sum test for differences between groups, we noted no significant difference in outcome between the treatment types (that is, pimozide, other typical [conventional] antipsychotics, and second-generation [atypical] antipsychotics) (Table 3c ).
Our follow-up analysis using the Yates-corrected chi-square test confirmed that the differences in outcome were not statistically significant. Although the data initially suggested the advantages of the newer medications, further analysis revealed a lack of statistical significance (P value only approached significance at the 0.05 level).
Clozapine Use
Four articles reported the use of clozapine (10-13) in the treatment of delusional disorder, with mixed results (Table 4 ). The sample was small (n = 5). Clozapine is reserved for use in cases of intractable side effects and treatment-resistant delusions. Its use here resulted from the failure of previous antipsychotic drug trials. Clozapine appeared to have little effect on the central delusional theme. That is, although each author noted a reduction in the associated symptoms of delusional disorder, the delusion often persisted. Interestingly, the articles suggested that the patients' quality of life improved when their treatment was switched to clozapine, despite the persistence of the delusions.
Outcome in Somatic Delusions Compared With Other Subtypes
Thirty-six percent of the reported cases (n = 80) experienced somatic delusions, in contrast with the 38% who experienced delusions of persecution (Table 3b) . Unfortunately, little treatment information was recorded for most of the patients with persecutory delusions.
In this updated review, we noted that 47/64 patients (73.4%) with somatic delusions were treated with pimozide. Using the Wilcoxon rank sum test, we found a significant difference in outcomes between delusion subtype groups (that is, somatic compared with other), based on the treatment received (P = 0.0004). That is, among patients treated with pimozide, there was a significant difference in outcome between those with somatic delusions and those with other types of delusions. As well, those treated with other types of medication showed a similar difference in outcome, despite the delusional theme.
A follow-up, Yates-corrected chi-square test confirmed a significant difference in outcome between patients with somatic-themed delusions and those with other delusion types.
Discussion
Despite certain limitations, the last decade's literature on delusional disorder treatment suggests optimism about the potential for treatment effectiveness. Of 131 reported cases, a positive response was noted in nearly 50%. This observation contrasts with widely held pessimism about treatment of delusional disorder. However, some caveats exist. First, the published literature seldom provides a forum for negative results, and clinicians may be reluctant to prepare reports on negative outcomes. Since case reports are the usual source of data, rather than controlled trials, they constitute our major source of evidence on this disorder. Thus the actual rate of successful treatment may be lower. Second, the lack of double-blind, randomized controlled studies raises concerns about the strength of the evidence for a positive response. Third, the frequent use of combination treatments suggests that monotherapy with antipsychotic medication may be insufficient in many cases. Fourth, the introduction of secondgeneration antipsychotics may have contributed to a reduced reliance on pimozide (68% and 44%, respectively), or it may reflect concern about pimozide's potential for QTc prolongation. Perhaps the more reliable outcome from these atypical antipsychotics, coupled with their reduced side effects, has resulted in reduced reliance on pimozide for treatment.
Conversely, claims about treatment effectiveness may be sound because factors such as nonadherence have not been adequately considered. In the earlier review, Munro commented that adherence to medication regimens was a central factor in treatment success (5) . The fact that, in case descriptions, so few studies in our review indicated the level of such adherence raises the possibility that this factor, when not specifically addressed, is critical to treatment success. Whether it might also be responsible for the difference in treatment response between patients with somatic delusions and those with other delusion types is a question for further investigation. One reasonable explanation for the differential success (patients with somatic delusions being more responsive) is adherence to medication regimens. Unfortunately, we do not have data to support this assertion. However, recognizing nonadherence to treatment among patients with delusional disorder is clearly relevant to understanding this phenomenon.
Indeed, the occurrence of any treatment success is noteworthy. The recovery rates we reported would be welcome in any clinic for any of the major psychotic disorders. Further, the general concordance of our review's observations with those of Munro and Mok's earlier review (5) strengthen the idea that delusional disorder should not be considered a treatment-resistant condition; medication can be effective if the patient adheres to the treatment regimen. In the cases we reviewed, clinicians possible overlooked or did not detect adherence problems and, in so doing, reinforced the perception that delusional disorder is difficult to treat, perhaps even treatment-resistant.
The newer, possibly more acceptable, second-generation antipsychotic agents had sporadic yet positive reports of treatment effectiveness associated with their use; the experience is thus far limited, but it parallels that of the older agents. All this Nonetheless, the observations from our review underscore the need for more focused research. Sample sizes were small, and controlled studies were almost nonexistent. There is a need to move beyond case reports to collaborative efforts in this area so that researchers can examine delusional disorder systematically in sufficient numbers to generate meaningful clinical conclusions.
Note A more extensive bibliography of articles consulted for this analysis, as well as of articles consulted but not used, is available from the corresponding author.
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Résumé : Progrès récents dans le traitement du trouble délirant
Objectif : Souvent considéré difficile à traiter dans le passé, même réfractaire au traitement, le trouble délirant est maintenant vu comme une affection traitable qui répond à la médication dans bien des cas. Munro et Mok ont précédemment examiné le dossier publié de ce traitement jusqu'en 1994. Le but de cette étude est de mettre à jour et d'élaborer leurs observations, et d'examiner l'effet des antipsychotiques de la deuxième génération sur le traitement de ce trouble.
Méthode : Nous avons tenté de colliger tous les articles publiés sur le trouble délirant, de 1994 à 2004, à l'aide de diverses stratégies de bases de données. Nous avons ensuite évalué ces articles en ce qui concerne la clarté, l'exhaustivité, le traitement, et les descriptions des résultats, sélectionnant ainsi un échantillon de patients aux fins d'analyse.
Résultats : Sur les 221 cas identifiés de trouble délirant, seulement 131 descriptions de cas ont fourni suffisamment de données sur le traitement et le résultat pour éclairer cette étude. Les données démographiques de cet échantillon étaient semblables à celles de l'étude précédente. La dépression comme affection comorbide était plus fréquente qu'auparavant. L'observance de la posologie du médicament était rarement abordée explicitement. La plupart des cas indiquaient une amélioration, peu importe le type d'antipsychotique que recevaient les patients. Le pimozide et autres antipsychotiques classiques, de même que les antipsychotiques de la deuxième génération et même la clozapine ont été utilisés dans nombre des études de cas.
Conclusions :
Une réponse positive au traitement pharmacologique a eu lieu dans presque 50 % des cas de notre étude, ce qui correspond à l'étude antérieure.
